ATE321782T1 - Membrantranslokierendes peptid als wirkstofftransportsystem - Google Patents

Membrantranslokierendes peptid als wirkstofftransportsystem

Info

Publication number
ATE321782T1
ATE321782T1 AT00968159T AT00968159T ATE321782T1 AT E321782 T1 ATE321782 T1 AT E321782T1 AT 00968159 T AT00968159 T AT 00968159T AT 00968159 T AT00968159 T AT 00968159T AT E321782 T1 ATE321782 T1 AT E321782T1
Authority
AT
Austria
Prior art keywords
mtlp
active agent
complex
membrane
active
Prior art date
Application number
AT00968159T
Other languages
English (en)
Inventor
Daniel J O'mahony
Imelda J Lambkin
Original Assignee
Elan Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Elan Corp filed Critical Elan Corp
Application granted granted Critical
Publication of ATE321782T1 publication Critical patent/ATE321782T1/de

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/48Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51Nanocapsules; Nanoparticles
    • A61K9/5107Excipients; Inactive ingredients
    • A61K9/513Organic macromolecular compounds; Dendrimers
    • A61K9/5146Organic macromolecular compounds; Dendrimers obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyamines, polyanhydrides
    • A61K9/5153Polyesters, e.g. poly(lactide-co-glycolide)
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22Hormones
    • A61K38/28Insulins
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/65Peptidic linkers, binders or spacers, e.g. peptidic enzyme-labile linkers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/10Dispersions; Emulsions
    • A61K9/127Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A61K9/1271Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475Growth factors; Growth regulators
    • C07K14/50Fibroblast growth factor [FGF]
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/87Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • C12N15/88Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation using microencapsulation, e.g. using amphiphile liposome vesicle

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Physics & Mathematics (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Dispersion Chemistry (AREA)
  • Microbiology (AREA)
  • Optics & Photonics (AREA)
  • Diabetes (AREA)
  • Nanotechnology (AREA)
  • Endocrinology (AREA)
  • Plant Pathology (AREA)
  • Toxicology (AREA)
  • Immunology (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AT00968159T 1999-09-27 2000-09-27 Membrantranslokierendes peptid als wirkstofftransportsystem ATE321782T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US15624699P 1999-09-27 1999-09-27

Publications (1)

Publication Number Publication Date
ATE321782T1 true ATE321782T1 (de) 2006-04-15

Family

ID=22558739

Family Applications (1)

Application Number Title Priority Date Filing Date
AT00968159T ATE321782T1 (de) 1999-09-27 2000-09-27 Membrantranslokierendes peptid als wirkstofftransportsystem

Country Status (7)

Country Link
EP (1) EP1230267B1 (de)
JP (1) JP4799790B2 (de)
AT (1) ATE321782T1 (de)
AU (1) AU7811000A (de)
CA (1) CA2386231C (de)
DE (1) DE60027030D1 (de)
WO (1) WO2001027154A2 (de)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6008202A (en) 1995-01-23 1999-12-28 University Of Pittsburgh Stable lipid-comprising drug delivery complexes and methods for their production
US20030181367A1 (en) * 1999-09-27 2003-09-25 O'mahony Daniel Conjugates of membrane translocating agents and pharmaceutically active agents
US6673574B2 (en) * 2000-11-30 2004-01-06 Unigene Laboratories Inc. Oral delivery of peptides using enzyme-cleavable membrane translocators
US7316819B2 (en) 2001-03-08 2008-01-08 Unigene Laboratories, Inc. Oral peptide pharmaceutical dosage form and method of production
DE60229867D1 (de) * 2001-07-02 2008-12-24 Merrion Res Iii Ltd Zielgerichtete ligande gegen peyer's flecke- und/oder m-zellen
JP2005511761A (ja) * 2001-07-10 2005-04-28 ノース・キャロライナ・ステイト・ユニヴァーシティ ナノ粒子送達ビヒクル
US8088734B2 (en) 2003-01-21 2012-01-03 Unigene Laboratories Inc. Oral delivery of peptides
US20050282756A1 (en) 2004-06-18 2005-12-22 Mehta Nozer M Oral delivery of peptide pharmaceutical compositions
GB0515115D0 (en) * 2005-07-22 2005-08-31 Isogenica Ltd Peptide characterisation
US8586081B2 (en) * 2007-09-20 2013-11-19 University Of Massachusetts Detoxified recombinant botulinum neurotoxin
CN107074910B (zh) * 2014-08-17 2022-02-18 塞里维瑞疗法公司 高级大分子转导域序列、编码其的多核苷酸及其用途
US20160060311A1 (en) 2014-08-27 2016-03-03 Daewoong Jo Development of Protein-Based Biotherapeutics That Penetrates Cell-Membrane and Induces Anti-Lung Cancer Effect - Improved Cell-Permeable Suppressor of Cytokine Signaling (iCP-SOCS3) Proteins, Polynucleotides Encoding the Same, and Anti-Lung Cancer Compositions Comprising the Same
US20170029798A1 (en) 2015-07-27 2017-02-02 Cellivery Therapeutics, Inc. Development of Improved Cell-Permeable (iCP) Parkin Recombinant Protein as a Protein-Based Anti-Neurodegenerative Agent for the Treatment of Parkinson's Disease-Associated Phenotypes by Utilizing BBB-Penetrating Protein Delivery System MITT, Enabled by Advanced Macromolecule Transduction Domain (aMTD)
WO2017026779A1 (en) 2015-08-10 2017-02-16 Cellivery Therapeutics, Inc. Improved cell-permeable cre (icp-cre) recombinant protein and use thereof
EP3334755B1 (de) 2015-08-10 2020-04-08 Cellivery Therapeutics, Inc. Verbessertes rekombinantes protein des zelldurchlässigen reprogrammierungsfaktors (icp-rf) und verwendung davon
EP3337815B1 (de) 2015-08-18 2020-12-16 Cellivery Therapeutics, Inc. Zellpermeables socs3-rekombinantes protein und verwendungen davon

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4675189A (en) * 1980-11-18 1987-06-23 Syntex (U.S.A.) Inc. Microencapsulation of water soluble active polypeptides
JP3618111B2 (ja) * 1993-11-05 2005-02-09 株式会社 メドレックス 有用物質の送達方法および膜認識シグナル
WO1998047913A2 (en) * 1997-04-18 1998-10-29 The University Of Medicine And Dentistry Of New Jersey Inhibition of hiv-1 replication by a tat rna-binding domain peptide analog
US6248558B1 (en) * 1998-03-31 2001-06-19 Vanderbilt University Sequence and method for genetic engineering of proteins with cell membrane translocating activity
WO1999064449A2 (en) * 1998-06-10 1999-12-16 The Queen's University Of Belfast Cell-permeable peptide

Also Published As

Publication number Publication date
CA2386231A1 (en) 2001-04-19
WO2001027154A3 (en) 2002-06-20
DE60027030D1 (de) 2006-05-18
AU7811000A (en) 2001-04-23
EP1230267B1 (de) 2006-03-29
EP1230267A2 (de) 2002-08-14
JP2003511464A (ja) 2003-03-25
WO2001027154A2 (en) 2001-04-19
JP4799790B2 (ja) 2011-10-26
CA2386231C (en) 2010-09-14

Similar Documents

Publication Publication Date Title
ATE321782T1 (de) Membrantranslokierendes peptid als wirkstofftransportsystem
Dekker et al. Substrate specificity of the integral membrane protease OmpT determined by spatially addressed peptide libraries
Eklund et al. Structural comparisons of mammalian, yeast and bacillar alcohol dehydrogenases
AU9315398A (en) Chemokine peptides, variants, derivatives and analogs. their use in methods to inhibit or augment an inflammatory response
AR033834A1 (es) Una proteina de fusion para liberar un compuesto a una celula, un metodo para liberar dicho compuesto, un metodo para identificar un peptido penetrador de membranas, y el uso de una proteina de fusion para la manufactura de un agente
PT1091975E (pt) Nova ciclosporina com um perfil de actividade melhorado
SE0201863D0 (en) Cell penetrating peptides
YU9404A (sh) Multimerna, usmerena kontrastna sredstva na bazi peptida
HRP20090003T3 (en) Oligopeptides for reducing elevated blood urea concentration
EP2570429A3 (de) Peptidvakzine mit Seq ID No: 48, 41, 44, 46 oder 78 für tumorassoziierte Antigene exprimierenden Krebs
WO2001080896A3 (en) Flavopiridol drug combinations and methods with reduced side effects
HK1039784A1 (zh) 抑制或增强炎症反應的化合物及方法
CA2435812A1 (en) Process and compositions for peptide, protein and peptidomimetic synthesis
AU7525398A (en) Inhibitors for urokinase receptor
GB2411404A (en) Biologically active peptide conjugates
CY1111004T1 (el) Χρησιμες συνθεσεις για τη ρυθμιση της δρασης του γονιδιου της παρκινης
WO2000044898A3 (en) Novel agouti and agouti-related peptide analogs
ATE223927T1 (de) Mu-opioidligande: agonisten und antagonisten
Moll et al. A biological stabilization technology for peptide drugs: enzymatic introduction of thioether-bridges
EP1796707A4 (de) Peptide mit spezifischem sitz in herzgefässen und verwandte konjugate und verfahren
DE602004019141D1 (de) Isoleucyl-valyl-threonyl-asparaginyl-threonyl-threonin (ivtntt) enthaltende biologisch wirksame peptide
WO2005072766A3 (en) Peptides that bind to hsp90 proteins
EP1758923B8 (de) Die myocardfunktion wiederherstellende peptidsubstanz
PE20001068A1 (es) Produccion de analogos de tripsinogeno recombinante solubles
WO2006052775A3 (en) Peptide anti - tumor agent

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties